Evotec (1EVT) AI Stock Analysis

Evotec

(Milan:1EVT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Integrated R&D platformEvotec’s integrated platform covers multiple stages of drug research, allowing it to support customers from discovery through development. This breadth can deepen client relationships, broaden revenue opportunities, and provide a durable foundation across changing pharmaceutical R&D priorities.

Negative Factors

Persistent unprofitability and margin pressureEvotec’s sustained losses and sharply compressed margins weaken the economics of its operating model and reduce its ability to fund growth internally. The gap between current and historical gross margins suggests profitability recovery may require meaningful improvement in mix, pricing, or costs.

Evotec (1EVT) vs. iShares MSCI Italy ETF (EWI)

Market Cap: EUR 500.65M
Dividend Yield: ―
Average Volume (3M): 4,109
Price to Earnings (P/E): -2.5
Beta (1Y): 0.78
Revenue Growth: -7.72%
EPS Growth: -26.61%
Country: Italy
Employees: 4,461
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Evotec Business Overview & Revenue Model

Company Description

Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a dive...

Evotec Risk Analysis

Evotec disclosed 10 risk factors in its most recent earnings report. Evotec reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Financial risksQ4, 2022

2.HR risksQ4, 2022

3.Strategic risksQ4, 2022

Evotec Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IT:1EVT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:MRK	68Neutral	EUR 65.78B	27.76	8.08%	1.45%	-0.40%	-17.22%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:B8FK	51Neutral	EUR 17.81M	-1.45	-127.78%	―	―	―
DE:BNN	44Neutral	EUR 61.61M	-4.27	590.52%	―	―	―
DE:HPHA	41Neutral	EUR 98.71M	-3.30	200.64%	―	206.78%	-13.94%

* General Sector Average

Performance Comparison

IT:1EVT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IT:1EVT	Evotec AG (UK)	2.83	-4.19	-59.68%
DE:B8FK	Biofrontera AG	2.93	0.26	9.74%
DE:BNN	B.R.A.I.N. Biotechnology Research and Information Network	2.82	0.49	21.03%
DE:MRK	Merck KGaA	151.30	41.75	38.11%
DE:HPHA	Heidelberg Pharma AG	2.11	-0.87	-29.19%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Evotec AI Stock Analysis